A Potential Solution for Acute Heart Failure Hospitalisation

By Staff Writer

January 17, 2024

Acute Heart Failure and its Impact

Acute Heart Failure (AHF) is a significant healthcare concern, affecting approximately six million people in the US. Projections suggest a dramatic increase in the cost of heart failure, from $3.7 billion in 2012 to $69.8 billion in 2030. The primary contributor to this increase is hospitalisation for AHF. Hospitalisation rates have been on the rise in the U.S, and mortality rates have been escalating since 2012. Moreover, lower socioeconomic status patients face a higher risk of hospitalisation and rehospitalisation in various conditions.

The Emergency Department (ED) and AHF

The Emergency Department (ED) is responsible for 70% to 80% of all AHF admissions in the U.S alone. A significant number of these admissions could potentially be avoidable. This is especially true for lower-risk patients. Hospitalising these patients could potentially expose them to unnecessary in-hospital adverse events and affect their quality of life.

Short-Stay Units (SSUs): A Potential Solution

Short-Stay Units (SSUs), offering brief periods of observation (<24 hours), have been supported for lower-risk patients with AHF. Prior studies have been conducted and have shown a shorter length of stay in SSU patients compared with inpatients. However, these studies were limited by their nonrandomised design.

The SSU-AHF Trial

The SSU-AHF trial was designed to overcome some of the previous limitations and evaluate outcomes in a randomised trial setting. The trial found no significant differences between SSU treatment and hospitalisation in terms of KCCQ-12 scores (a measure of quality of life) at day 3. However, the number of Days Alive Out Of Hospital (DAOOH) at 30 days significantly increased in the SSU group.

Implications of the SSU-AHF Trial

The SSU-AHF trial suggests that SSUs offer a safe alternative setting for trying novel approaches to risk stratification, ongoing treatment, and rigorous self-care assessment. While the study did not show a significant benefit of SSU over hospitalisation, it does however support the consideration of SSU management instead of routine hospital admission. This would potentially assist with overcoming some of the increased cost expected to arise in the near future.

Limitations and Conclusions

The SSU-AHF trial had some limitations, including a relatively small sample size and the impact of the COVID-19 pandemic on study parameters. We need more randomised clinical trial data to definitively test the SSU strategy’s benefits.

Reference url

Recent Posts

oral cancer East Africa
   

Oral Cancer in East Africa: The Need for Early Detection

💡 Did you know that Toombak use is a leading risk factor for oral cancer in East Africa?

A recent scoping review sheds light on the shocking prevalence of oral cancer in the region, emphasising the urgent need for public health interventions and improved early detection strategies. Enhancing awareness around risk factors like Toombak, tobacco, and alcohol for tackling this growing health crisis.

Curious about the key insights and their implications for health economics? Look into the full article to find out more!

#SyenzaNews #HealthEconomics #Oncology #GlobalHealth

Novartis patent cliff layoffs
     

Engineering Resilience: Mastering Pharma Patent Expiration Strategy

🚨 Are you still reacting to pharmaceutical patent expirations with layoffs and litigation, or are you ready to engineer a strategy that turns the patent cliff into your next competitive edge?

Patent expirations don’t have to derail your pharma portfolio. Learn how to outmaneuver generics and transform challenges into advantages. Dive into our latest insights and take control today.

#SyenzaNews #pharmaceuticals #innovation #PharmaStrategy #patentcliffs

diabetes medicine access
               

Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefits Scheme

🚀 Are we on the verge of a breakthrough in diabetes medication accessibility?

The latest updates to the Pharmaceutical Benefits Scheme (PBS) are set to transform type 2 diabetes management by expanding access to essential medicines like empagliflozin and streamlining the prescribing process for glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These changes not only prioritize equity for high-risk populations but also align with global trends in cost-effective healthcare.

Dive deeper into how these revisions could reshape diabetes care and promote better health outcomes for all.

#SyenzaNews #HealthcareInnovation #healthcare #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.